Alx Oncology Holdings (NASDAQ:ALXO) — Market Cap & Net Worth
Market Cap & Net Worth: Alx Oncology Holdings (ALXO)
Alx Oncology Holdings (NASDAQ:ALXO) has a market capitalization of $235.07 Million ($235.07 Million) as of September 20, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16018 globally and #3796 in its home market, demonstrating a -10.53% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alx Oncology Holdings 's stock price $1.70 by its total outstanding shares 138276997 (138.28 Million). Also see Alx Oncology Holdings balance sheet assets for a full breakdown of the balance sheet.
Alx Oncology Holdings Market Cap History: 2020 to 2026
Alx Oncology Holdings 's market capitalization history from 2020 to 2026. Data shows change from $11.92 Billion to $235.07 Million (-37.18% CAGR). Also see Alx Oncology Holdings cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Alx Oncology Holdings is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.65 Trillion | 0.01% | #439 of 976 |
|
NASDAQ Composite
IXIC
|
$42.00 Trillion | 0.00% | #1571 of 3165 |
Weight: Alx Oncology Holdings 's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alx Oncology Holdings Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alx Oncology Holdings 's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ALXO share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
10084.16x
Alx Oncology Holdings 's market cap is 10084.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $11.92 Billion | $1.18 Million | -$45.74 Million | 10084.16x | N/A |
Competitor Companies of ALXO by Market Capitalization
Companies near Alx Oncology Holdings in the global market cap rankings as of September 20, 2026. Review tangible equity quality of Alx Oncology Holdings to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Alx Oncology Holdings by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Alx Oncology Holdings Historical Marketcap From 2020 to 2026
Between 2020 and today, Alx Oncology Holdings 's market cap moved from $11.92 Billion to $ 235.07 Million, with a yearly change of -37.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $235.07 Million | +50.44% |
| 2025 | $156.25 Million | -32.34% |
| 2024 | $230.92 Million | -88.78% |
| 2023 | $2.06 Billion | +32.12% |
| 2022 | $1.56 Billion | -47.56% |
| 2021 | $2.97 Billion | -75.07% |
| 2020 | $11.92 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Alx Oncology Holdings was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $235.07 Million USD |
| MoneyControl | $235.07 Million USD |
| MarketWatch | $235.07 Million USD |
| marketcap.company | $235.07 Million USD |
| Reuters | $235.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more